Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AbbVie, Genentech, Takeda Oncology, Novartis Pharmaceuticals Corporation, and Onyx Pharmaceuticals.

18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

February 14 - 15, 2014
Crowne Plaza® Times Square - Manhattan
New York, NY


The 18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides a unique opportunity for medical oncologists, hematologists, and other health care professionals to learn from and to interact with international leaders in the field of hematologic malignancies in order to increase knowledge, apply new data and to practice and improve patient outcomes.

Target Audience

This educational activity is directed toward community-based hematologists, medical oncologists, and fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners (NPs), nurses, physician assistants (PAs), pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.

Click here to download brochure

Educational Objectives

  • Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of hematologic malignancies, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
  • Summarize the genomic and molecular biomarkers that have been integrated into risk assessment and treatment selection paradigms for patients with hematologic malignancies
  • Compare efficacy and safety data supporting treatment options in order to optimize outcomes for individual patients
  • Describe current strategies for Individualizing therapy for patients with newly diagnosed hematologic malignancies  based on assessment of transplant eligibility, patient and tumor characteristics, and risk/benefit profiles of available regimens
  • Summarize optimal supportive care strategies for preventing and treating side effects related to hematologic malignancies or their treatment
  • Select eligible patients with hematologic malignancies for promising clinical trials

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with the ACCME Standards for Commercial Support , PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to start of each activity. Participants are notified prior to the activity of the presence or absence of relevant financial relationships between faculty and commercial interests. Information disclosed includes the name of the faculty, nature of the relevant financial relationship (e.g., member of speaker’s bureau, grant/research support, or consulting arrangement), and the name of the company/organization with which the relationship exists. Additionally, prior to the start of each activity PER® discloses the source of commercial support to the participants.

Faculty and Staff Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose:

Lisa DeAngelis, MD ; Randy Gascoyne, MD; Issa F. Khouri, MD; Thomas Kipps, MD, PhD; Ola Landgren, MD, PhD; Mark R. Litzow, MD; Susan Seo, MD; Catherine Wu, MD; Joachim Yahalom, MD

The staff of PER®, LLC: Leigh Anne Bongiovanni; Ann C. Lichti, CCMEP; Dru Dace, PhD; and Megan O'Connell.

The following individuals have relevant financial relationships with commercial interests to disclose:

James Berenson, MD Grant/Research Support: Millennium; Celgene; Novartis; Amgen; Consultant: Celgene; Onyx; Novartis; Amgen; Millennium; Speaker’s Bureau: Celgene; Onyx; Novartis; Millennium; Leif Bergsagel, MD Consultant: Onyx; Renier J. Brentjens, MD, PhD Stock/Shareholder: Juno Therapeutics; Jennifer Brown, MD, PhD Grant/Research Support: Celgene; Consultant: Pharmacyclics; Genentech; Emergent; Onyx; sanofi-aventis; Vertex; Novartis; Celgene; Boehringer; Gilead Sciences; GSK; Dan Douer, MD Consultant: Sigma Tau; Amgen; BMS; Harry Erba, MD, PhD Grant/Research Support: Celator; Millennium; Seattle Genetics; Amgen; Consultant: Novartis; Incyte; Seattle Genetics; Amgen; Speaker’s Bureau: Incyte; Novartis; Alessandra Ferrajoli, MD Grant/Research Support: Celgene; Andre Goy, MD Speaker’s Bureau: Millennium; Janssen; Advisory Board: Celgene; Janssen; Paul Hamlin, MD Grant/Research Support: Spectrum; SGN; GSK; J&J; Consultant: Spectrum; Pfizer; Gilead; Sundar Jagannath, MD - Consultant: Celgene Corporation, Millennium Pharmaceuticals, and Merck & Co, Inc.; Ari Melnick, MD Consultant: Celgene; Speaker’s Bureau: Genentech; BioReference; Ruben Mesa, MD, FACP Grant/Research Support: Incyte; Genentech; Lillly; NS Pharma; Craig H. Moskowitz, MD Grant/Research Support: Seattle Genetics; Roche; Plexxikon; Merck; Speaker’s Bureau: Janssen; Seattle Genetics; Roche; GlaxoSmithKlein; John Radford, MD Grant/Research Support: Millennium/Takeda; Consultant: Seattle Genetics; Millennium/Takeda; Speaker’s Bureau: Seattle Genetics; Charles Schiffer, MD Grant/Research: Novartis; BMS; Ariad; Celgene; Pfizer; Consultant: BMS; Teva; Celgene; Millennium; Pfizer; Speaker’s Bureau: BMS; A. Keith Stewart, M.B.Ch.B. Grant/Research Support: Millennium; Onyx; Consultant: Celgene; Array Pharma; BMS; William G. Wierda, MD, PhD Grant/Research Support: Genentech; Abbvie; GSK; Consultant: Genentech; Abbvie; GSK; Pharmacyclics; Gilead; Celgene; Anas Younes, MD Research/Grant Support: Novartis; J&J; Seattle Genetics; Merck; Genentech; Gilead; Honorarium: Novartis; Seattle Genetics; Millennium; Celgene; Curis; sanofi-aventis; Pharmacyclics; Incyte; Andrew D. Zelenetz, MD, PhD Research: Roche, GlaxoSmithKline, and Genentech; Consultant: Seattle Genetics, sanofi-aventis USA, GlaxoSmithKline, Gilead, Cephalon, and Celgene; Scientific Advisor: Cancer Genetics.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By